Allarity Therapeutics Terminates $6 Million Stock Sale Deal With Tumim Stone Capital
Allarity Therapeutics has ended its share sale agreement with Tumim Stone Capital, which allowed sales of up to $6 million. No early termination penalty applies.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
On October 28, 2026, Allarity Therapeutics ended its common stock purchase agreement with Tumim Stone Capital. The deal, signed on January 28, 2026, let the company sell up to $6.0 million of shares whenever it chose.
According to the company, the early termination carries no penalty. Allarity plans to pursue other financing arrangements and will not sell any more shares to Tumim under this agreement.
The details come from a TradingView report, which is based on documents filed with the SEC.
why it matters
For markets the news is of limited scope: such agreements give a company a way to raise capital in small tranches, and cancelling one signals a change in funding sources. No details of the new arrangement have been disclosed, so it is too early to judge the effect on the company's shares.
tags
instruments
sources
- Allarity Therapeutics Ends $6 Million Stock Purchase Agreement With Tumim — TradingView, 30 October 2026 at 20:13 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗